Genta Incorporated (OTCBB: GNTA) announced the presentation of a progress update from the Company's ongoing Phase 3 trial of Genasense(R) (oblimersen sodium) Injection, Genta's lead oncology product, in patients with advanced melanoma.

BERKELEY HEIGHTS, N.J., July 14 /PRNewswire-FirstCall/ -- Genta Incorporated (BULLETIN BOARD: GNTA) announced that the Food and Drug Administration (FDA) has accepted the Company's amendment to its New Drug Application (NDA) for Genasense(R) (oblimersen sodium) Injection as a "complete response".

BERKELEY HEIGHTS, N.J., June 10 /PRNewswire-FirstCall/ -- Genta Incorporated (BULLETIN BOARD: GNTA) announced that the Company has received notice of allowances for two major patents from the European Patent Office for its pipeline product, tesetaxel, a leading oral taxane.

BERKELEY HEIGHTS, N.J., June 6 /PRNewswire-FirstCall/ -- Genta Incorporated (BULLETIN BOARD: GNTA) announced that the Company has submitted an amendment to the Food and Drug Administration (FDA) for its New Drug Application (NDA) for Genasense(R) (oblimersen sodium) Injection plus chemotherapy for patients with relapsed or refractory chronic lymphocytic leukemia (CLL).

BERKELEY HEIGHTS, N.J., June 5 /PRNewswire-FirstCall/ -- Genta Incorporated (BULLETIN BOARD: GNTA) announced today that the Company has entered into definitive agreements with institutional and accredited investors to place Senior Secured Convertible Notes due 2010 totaling in aggregate up to $40 million in gross proceeds before fees and expenses.